At a glance: Semaglutide — sold as Ozempic for diabetes and Wegovy for weight management — is a once-weekly injectable GLP-1 receptor agonist. In clinical trials, patients typically lost 10–15% of body weight over about 68 weeks when combined with lifestyle changes. It is a prescription medication with real contraindications and side effects; candidacy is determined at a medical consultation. OC Weight Loss & Med Spa in Mission Viejo, CA offers supervised semaglutide programs under physician oversight.
Medically reviewed by the clinical team at OC Weight Loss & Med Spa. Last updated: June 12, 2026.
What is semaglutide?
Semaglutide is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone the gut releases naturally after eating. GLP-1 signals the brain to reduce appetite and tells the pancreas to release insulin in response to rising blood sugar. Because semaglutide mimics this hormone and resists rapid breakdown, a single weekly injection can sustain those effects for days.
The FDA first approved semaglutide as Ozempic in 2017 for type 2 diabetes management. Physicians noticed consistent, substantial weight loss in patients — enough to prompt dedicated trials. In 2021 the FDA approved a higher-dose formulation, Wegovy, specifically for chronic weight management in adults with obesity or overweight with a weight-related condition.
How semaglutide produces weight loss
Three interlocking mechanisms drive the weight-loss effect.
- Appetite suppression. Semaglutide acts on receptors in the hypothalamus, the brain region that governs hunger. Patients typically feel satisfied with smaller portions and report fewer food cravings.
- Delayed gastric emptying. Food moves more slowly from the stomach to the small intestine, extending the feeling of fullness after a meal.
- Improved glycemic control. By stimulating insulin release and suppressing glucagon only when blood sugar rises, semaglutide helps stabilize energy levels and reduces the blood-sugar swings that can drive overeating.
These effects work together to make it easier to sustain a moderate calorie deficit — the underlying driver of weight loss. The medication does not burn fat directly; it changes the hormonal environment so that behavioral change becomes more achievable. Individual results vary.
What to expect: realistic outcomes
In the STEP clinical trial program, adults using semaglutide 2.4 mg (Wegovy) alongside lifestyle counseling lost an average of approximately 15% of body weight at 68 weeks, compared to about 2.4% in the placebo group. Some participants lost more; some lost less. Results depend on starting weight, adherence, diet quality, physical activity, and metabolic factors.
Most patients notice reduced hunger within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight. Maximum effect is generally reached around the 60–68 week mark with consistent use. Weight can return after discontinuation, so many patients and providers plan for long-term management rather than a fixed course.
Safety, side effects, and who should not use semaglutide
Semaglutide is a prescription medication with a meaningful safety profile. Understanding the risks is part of an informed decision.
Common side effects are mainly gastrointestinal and occur most often during dose escalation:
- Nausea (most frequent, affects roughly 40–50% of users early on)
- Vomiting, diarrhea, or constipation
- Stomach discomfort or bloating
- Decreased appetite (expected, but can occasionally be excessive)
These effects usually diminish as the body adjusts over weeks. Starting at a low dose and escalating slowly — as the prescribing protocol specifies — significantly reduces their severity.
Boxed warning — thyroid C-cell tumors: In rodent studies, semaglutide caused thyroid C-cell tumors. It is not known whether this risk applies to humans, but semaglutide carries an FDA boxed warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other contraindications and precautions include:
- Personal or family history of MTC or MEN 2 (absolute contraindication)
- Pregnancy or planned pregnancy — GLP-1 agonists are not recommended during pregnancy
- Personal history of pancreatitis — use requires careful evaluation
- Severe renal or hepatic impairment
- Diabetic retinopathy complications in patients with type 2 diabetes (risk of worsening)
- Hypoglycemia risk when combined with insulin or sulfonylureas
Candidacy for semaglutide is determined at a medical consultation. A qualified provider reviews your full health history, current medications, and weight-loss goals before prescribing.
Semaglutide at OC Weight Loss & Med Spa
OC Weight Loss & Med Spa is a physician-supervised weight-loss and medical aesthetics practice in Mission Viejo, CA. The program is led by Lindsay Short, NP, a board-certified Nurse Practitioner, under the oversight of Dr. Nezar Dahdal, MD, board-certified in Internal Medicine.
Semaglutide is prescribed as part of a structured program that includes an initial medical evaluation, individualized dosing, ongoing monitoring, and lifestyle guidance. The goal is sustainable fat loss with clinical support at each stage — not a standalone prescription with no follow-up.
Frequently asked questions
Is semaglutide the same as Ozempic?
Semaglutide is the active ingredient. Ozempic is the brand name approved for type 2 diabetes at doses up to 2 mg per week. Wegovy is the brand name approved for chronic weight management at 2.4 mg per week. Both contain semaglutide; the difference is the approved indication and dose. A provider will prescribe the appropriate formulation based on your individual situation.
How long does it take to see results?
Most patients notice reduced appetite within the first one to two weeks. Visible weight loss typically begins within the first month and continues progressively. Clinical trials show that the largest cumulative weight loss occurs around 60–68 weeks. Progress is gradual by design — rapid weight loss has its own risks.
Do I need to change my diet while taking semaglutide?
Semaglutide reduces appetite; it does not substitute for nutrition. Patients who pair the medication with a balanced, protein-adequate diet and regular physical activity typically achieve better and more lasting results than those who rely on the medication alone. Your provider at OC Weight Loss & Med Spa will give you practical guidance tailored to your lifestyle.
What happens if I stop taking semaglutide?
When semaglutide is discontinued, appetite-regulating hormone levels shift back toward baseline. Many patients regain a portion of the weight they lost, particularly without sustained lifestyle changes. This is not a failure of the medication — weight management is often a long-term endeavor. Your provider can help you plan a maintenance strategy appropriate to your health goals.
Can I use semaglutide if I don’t have diabetes?
Yes. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. You do not need a diabetes diagnosis to be a candidate. Your provider will determine eligibility based on your full health history.
Ready to explore semaglutide as part of a medically supervised plan?
The team at OC Weight Loss & Med Spa offers a free consultation to review your health history, discuss candidacy, and outline a realistic plan. The clinic is located at 24002 Via Fabricante #201, Mission Viejo, CA 92691. You can also call (949) 416-0950 or visit our contact page with questions. Financing options including Cherry, CareCredit, and Alle are available.
Book a free consultation
Book a Free Consultation